针对Fyn和GSK-3β进行双目标神经调节的选择性7-阿赞醇调节剂
Haofeng Shi1, Yinlong Li1, Steven H Liang1,2
1Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States.
ACS medicinal chemistry letters
|January 14, 2026
概括
研究人员开发了针对神经退行性疾病的Fyn原瘤基因激酶 (Fyn) 和糖原合成酶激酶-3β (GSK-3β) 的双重抑制剂. 这些新型化合物显示出开发下一代神经再生疗法的前景.
科学领域:
- 生物化学 生物化学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 芬原基因激酶 (Fyn) 和糖原合成酶激酶-3β (GSK-3β) 是关键蛋白激酶,参与神经退行.
- 对Fyn和GSK-3β的失调与神经疾病的进展有关.
- 用抑制剂向这些激酶是研究的一个活跃领域.
研究的目的:
- 设计和开发针对Fyn和GSK-3β的新型双重抑制剂.
- 探索多位抑制剂在神经退行性疾病中的治疗潜力.
- 为下一代神经再生疗法奠定基础.
主要方法:
- 结构-活性关系 (SAR) 优化被用于设计抑制剂.
- 一系列双选择性纳米分子抑制剂被合成和表征.
- 对化合物的神经保护和调节性质进行了深入的分析.
主要成果:
- 成功开发了一系列针对Fyn和GSK-3β的双选择性纳米分子抑制剂.
- 化合物显示出显著的神经保护和调节作用.
- 该研究为进一步的药物开发奠定了坚实的基础.
结论:
- 对Fyn和GSK-3β的双抑制代表了神经退行性疾病的有前途的治疗策略.
- 开发的抑制剂为神经再生疗法提供了潜在的新途径.
- 对这些化合物的进一步研究可能会导致神经系统疾病的新治疗方法.
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
814
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
814
Targets for Drug Action: Overview
10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K


